South Tees Healthcare Management Limited
Registered name: SOUTH TEES HEALTHCARE MANAGEMENT LIMITED
South Tees Healthcare Management Limited made £22.5m revenue and a £99.6k loss in the year to 31 Mar 2025. read from filing text
South Tees Healthcare Management Limited’s revenue grew 8% to £22.5m in the year to 31 Mar 2025, with a loss of £99.6k and 21 employees. The company is classified under “research and experimental development on biotechnology” and is based in Middlesbrough; we hold 3 years of its filed accounts.
- Status
- Active
- Location
- Middlesbrough, North East
- Age
- 10 yrs · since 2016
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “The ultimate parent and controlling parent of the Company is South Tees Hospitals NHS Foundation Trust, which is part of a public benefit group and under the ultimate control of the Department of Heal”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Mar 2023 | 31 Mar 2024 | 31 Mar 2025 |
|---|---|---|---|
| Disclosure | Full P&Lread from filing text | Full P&Lread from filing text | Full P&Lread from filing text |
| Profit & loss | |||
| Revenue (turnover) | £20.6m | £20.9m | £22.5m |
| Cost of sales | £20.6m | £20.7m | £22.5m |
| Gross profit | £20.1k | £137k | £12k |
| Profit before tax | £6.3k | £29.5k | −£133k |
| Profit after tax | £10.4k | £22.2k | −£99.6k |
| Profit (best available) | £10.4k | £22.2k | −£99.6k |
| Staff costs | £637k | £763k | £805k |
| Employees (average) | 18 | 19 | 21 |
| Ratios | |||
| Profit margin | 0.1% | 0.1% | −0.4% |
| Gross margin | 0.1% | 0.7% | 0.1% |
| Revenue per employee | £1.1m | £1.1m | £1.1m |
| Profit per employee | £580 | £1.2k | −£4.7k |
| Growth (year on year) | |||
| Revenue growth | — | ▲1.3% | ▲7.9% |
| Profit growth | — | ▲112.3% | ▼549.6% |
| Headcount growth | — | ▲5.6% | ▲10.5% |
| Balance sheet — indirect signals, not revenue | |||
| Cash at bank | £598k | £594k | £916k |
| Net assets | −£74.4k | −£52.3k | −£152k |
| Current assets | £2.7m | £2.6m | £3.4m |
| Debtors | £983k | £0 | £7.3k |
| Deferred income | £2.7k | £1.4k | £1.4k |
| Source | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Dec 2024 | FullAccounts · bulk data Dec 2025 |
How the business works
- Profit margin
- −0.4%
- Profit ÷ revenue.
- Gross margin
- 0.1%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £1.1m
- Revenue ÷ average employees.
- Profit per employee
- −£4.7k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 0%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 0%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now −£152k
- Cash at bank
- ▲54%
- Now £916k
- Headcount
- ▲11%
- Now 21
- Deferred income
- 0%
- Now £1.4k
- Fixed assets
- —
- Now —
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Group structure
Minority corporate shareholders
- South Tees Hospitals Nhs Foundation Trust (registered outside the UK register)
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Origio LimitedFareham · Research and experimental development on biotechnology
- Revenue
- £20.1m
- Profit
- £499k
- Staff
- 82
- Enara Bio LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £17.4m
- Profit
- £1.3m
- Staff
- 54
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Theradex (Europe) LimitedRedhill · Research and experimental development on biotechnology
- Revenue
- £15.2m
- Profit
- £3.1m
- Staff
- 43
Sources
Latest figures from FullAccounts for the year to 31 Mar 2025 (profit −£99.6k), from the Companies House accounts bulk data published Dec 2025. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.